CLDN22 Serves as a Novel Prognostic Biomarker and Immunotherapy Response Predictor in Gliomas: A Comprehensive Multiomics Analysis.

ABSTRACT:

Background

The claudin gene family plays crucial roles in cancer biology, yet their comprehensive molecular characteristics and clinical implications in gliomas remain unclear.

Methods

Multiomics data from The Cancer Genome Atlas (TCGA) were analyzed, and differential expression analysis was performed between glioma and normal samples. Consensus clustering was applied to identify molecular subtypes. Multiple machine learning algorithms, including least absolute shrinkage and selection operator (LASSO), extreme gradient boosting (XGBoost), Boruta, prediction analysis of microarrays (PAMR), and random forest, were employed for feature selection. Immune characteristics were evaluated using Estimation of STromal and Immune cells in MAlignant Tumors using Expression data (ESTIMAT

SUBMITTER: Zheng H 

PROVIDER: S-EPMC12717531 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature